Eugenics conspiracies aside:
Big Pharma is in big trouble - most of their big-profit blockbusters are about to go off patent. Between now and 2015,
$250 billion in drug sales are about to
into the generics market.
So Big Pharma is pushing for another "bail-out" by withholding essential products.
A bit like a union strike or human peoples' riots
for food and justice, except Big Pharma is campaigning for the corporate right to profit
Corporations are just profit-making machines. They don't care
. They can't. Despite their alleged legal personhood, they are not human.
Really, they are just a legal idea
. And corporate law says corporations must
put profits before people, even if people die.
Drugs going off-patent in 2011 include:
The 10 Biggest-Selling Drugs That Are
About to Lose Their Patent
The imminent arrival of the dreaded "patent cliff" has been haunting the pharmaceutical industry for years, and it's finally here. With patents on
many blockbuster drugs about to expire, an estimated $250 billion in sales are at risk between now and 2015…
1. Lipitor - made by Pfizer - US sales worth $5,329,000,000
2. Zyprexa - made by Eli Lily - US sales worth $2,496,000,000
3. Levaquin - made by Johnson & Johnson - US sales worth $1,312,000,000
4. Concerta - made by Johnson & Johnson - US sales worth $929,000,000
5. Protonix - made by Pfizer - US sales worth $690,000,000
Drugs going off-patent in 2012 include:
6. Plavix - made by Bristol-Myers Squibb /
Sanofi-Aventis - US sales worth $6,154,000,000
7. Seroquel - made by AstraZeneca - US sales worth $3,747,000,000
8. Singulair - made by Merck - US sales worth $3,224,000,000
9. Actos - made by Takeda - US sales worth $3,351,000,000
10. Enbrel - made by Amgen - US sales worth $3,304,000,000
* Pfizer (PFE)
. Along with Lipitor and Protonix, Pfizer markets Enbrel outside the U.S., Canada and Japan with 2010 sales for Enbrel at
$3.2 billion. Drugs losing patent protection between 2010 and 2012 make up 42% of Pfizer's pharmaceutical
* Eli Lilly (LLY)
. Zyprexa's worldwide revenues were just over $5 billion in 2010 - nearly 22% of Lilly's full year sales. Zyprexa's
patent expires in October, and Lilly could fall off the patent cliff along with Pfizer.
* Johnson & Johnson (JNJ).
J&J is more diversified than most Big Pharma companies but still looks to lose $1.4 billion and $1.3 billion
in worldwide sales of Levaquin (levofloxacin) and Concerta (methylphenidate). That's 12% of the $22.4 billion in drug revenues and 4% of the
company's total $61.6 billion in revenues.
* Sanofi-Aventis (SNY)
and Bristol-Myers Squibb (BMY)
co-developed and co-market Plavix. Bristol reported $6.7 billion in
Plavix sales in 2010 - 34% of its total revenues of $19.5 billion. Sanofi reported over 2 billion euros (roughly $2.7 billion) in Plavix sales - 7% of
its 30 billion euros revenues in 2010. Plavix's patent is set to expire on May 17, 2012.
In 2010, Sanofi said generic competition caused loss of more than 2 billion euros in sales.
* AstraZeneca (AZN).
Seroquel's worldwide sales amounted to $5.3 billion in 2010 - nearly 16% of Astra's revenues. Originally set
expire in September 2011, Seroquel was given a six-month extension from the FDA.
Drugs generating 62% of Astra's 2009 revenue go off-patent by 2014.
* Merck (MRK).
Worldwide sales for Singulair were $5 billion in 2010 - nearly 11% of Merck's total revenue. Merck's blood pressure
drugs Cozaar/Hyzaar already went off-patent and sales slumped by 41% in 2010 to $2.1 billion - but has already recovered lost revenue from other
drugs' patent expiry or withdrawal, including Vioxx (withdrawn in 2004), Proscar (2005), Zocor (2006), Fosamax (2008) and Cozaar (2010).
Reported sales were 293 billion yen ($3.58 billion), or 27% of its total revenue for Actos in the 1st 9 months of 2010. Actos
patent expired in January 2011, but Takeda negotiated a reprieve til August 2012.
* Amgen (AMGN).
Enbrel accounted for 23% of Amgen's total revenue in 2010 - with total sales at $3.5 billion.
Drug prices to plummet as
expiring patents allow generic competition
Big Pharma's Patent Headache
Drugmakers Hike Prices
of Meds Facing Generic Competition